Posting of Circular and Notice of General Meeting
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, further to the announcement made on 30 October 2025, a circular (the "Circular"), including the Notice of General Meeting and a Form of Proxy, has been posted to shareholders.
The General Meeting will be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London, EC4R 3TT at 11 a.m. on 20 November 2025.
A copy of the Circular will shortly be available on the Company's website at https://www.valirx.com/aim-rule-26.
Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 30 October 2025.
FUNDRAISING STATISTICS
| Issue Price | 0.25 pence |
|---|---|
| Number of Existing Shares | 374,348,672 |
| Number of Tranche 1 Placing Shares | 112,304,600 |
| Number of Tranche 2 Placing Shares | 183,695,400 |
| Aggregate Number of Placing Shares | 296,000,000 |
| Number of WRAP Retail Offer Shares | 60,722,400 |
| Number of Subscription Shares | 4,000,000 |
| Number of Fee Shares | 7,650,000 |
| Aggregate Number of New Ordinary Shares to be issued in connection with the Fundraising | 368,372,400 |
| Number of Shares in issue following Admission and issue of the New Ordinary Shares | 742,721,072 |
| Percentage of the Enlarged Share Capital represented by the New Ordinary Shares | 49.60% |
| Number of Fundraising Warrants to be issued following Admission | 368,372,400 |
| Number of Broker Warrants to be issued following Admission | 16,036,120 |
| Gross proceeds of the Placing | £740,000 |
| Gross proceeds of the WRAP Retail Offer | £152,000 |
| Gross proceeds of the Subscription | £10,000 |
| Gross proceeds of the Fundraising | £902,000 |
| Ordinary Share ISIN | GB00BLH13C52 |
| EXPECTED TIMETABLE OF PRINCIPAL EVENTS | |
| 2025 | |
| Announcement of the Fundraising | 30 October |
| Launch of the WRAP Retail Offer | 30 October |
| Date of publication and posting of this Circular & the Form of Proxy | 4 November |
| Announcement of the results of the WRAP Retail Offer | 4 November |
| Admission and dealings in the Tranche 1 Placing Shares expected to commence on AIM | 8:00 a.m. on or around 6 November |
| Expected date for CREST accounts to be credited for Tranche 1 Placing Shares to be held in uncertificated form | 6 November |
| Despatch of definitive share certificates in respect of the Tranche 1 Placing Shares to be held in certificated form, if applicable | by 20 November |
| Latest time and date for receipt of CREST Proxy Votes or the completed Forms of Proxy | 11.00 a.m. on 18 November |
| General Meeting | 11.00 a.m. on 20 November |
| Announcement of the results of the General Meeting | 20 November |
| Admission and dealings in the Tranche 2 Placing Shares, Subscription Shares, Fee Shares and WRAP Retail Offer Shares expected to commence on AIM | 8:00 a.m. on or around 21 November |
| Expected date for CREST accounts to be credited for Tranche 2 Placing Shares, Subscription Shares, WRAP Retail Offer Shares, Fee Shares and Fundraising Warrants to be held in uncertificated form | 21 November |
| Despatch of definitive share certificates in respect of the Tranche 2 Placing Shares, Subscription Shares, WRAP Retail Offer Shares, Fee Shares and Fundraising Warrants to be held in certificated form, if applicable | by 5 December |
Notes:
- Each of the times and dates above are indicative only and if any of the details contained in the timetable above should change, the revised times and dates will be notified to Shareholders by means of an announcement through a Regulatory Information Service.
- All of the above times refer to London time unless otherwise stated.
- All events listed in the above timetable related to the granting of the Fundraising Warrants and the Broker Warrants and Admission of the Tranche 2 Placing Shares, the Subscription Shares, the WRAP Retail Offer Shares and the Fee Shares are conditional on the passing at the General Meeting of the Fundraising Resolutions to provide the relevant authorities.
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/yVwkje |
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 115 784 0026 www.valirx.com Mark.Eccleston@valirx.com |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
| Shard Capital Partners LLP (Broker) Damon Heath Andrew Gutmann | Tel: +44 (0) 20 7186 9000 |
| SP Angel Corporate Finance LLP (Placing Agent) David Hignell Vadim Alexandre | Tel: +44 (0) 20 3470 0470 |
| V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director | +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz |
Background to and Reasons for the Fundraising
ValiRx is an AIM-quoted life science company focused on cancer therapeutics and women's health. The Company seeks to identify the most promising research in academia and innovative biotechnology companies and translate this research towards clinical development, providing a pathway to commercialisation.
The Company has identified certain fundamental issues impacting drug development today, in terms of innovation, productivity and access. A lack of expertise in early-stage drug developers, particularly in academia, contributes to low rates of success in translating novel scientific research into valuable new therapeutic assets, hindering both the adoption of innovation and the overall productivity of developing new treatments.
To address these fundamental issues, ValiRx has adopted a strategy to improve the efficacy of translating promising novel research into the preclinical development phase, with a particular focus on women's health and oncology. Combining its clinical knowledge, deep biological expertise, data generation and data interpretation abilities, ValiRx seeks to unlock the substantial potential of early-stage innovation and provide a specialist service for its in-house collaborative projects and third-party innovators through its subsidiary, Inaphaea Biolabs Limited ("Inaphaea").
Use of Proceeds
The proceeds of the Fundraising, in aggregate of approximately £902,000 (before expenses), are intended to be used by the Group for the following:
Estimated cost
| · R&D: invest into the ValiRx future collaborative pipeline | £0.4m |
| · R&D: preclinical development of Cytolytix | £0.2m |
| · R&D: preclinical development of VAL201 2.0 | £0.05m |
| · Operating costs (balance from R&D tax credits, revenue and grants) | £0.25m |
For the purposes of section 571(6)(c) of the Companies Act 2006, the Issue Price has been determined by the Company following discussions with market participants and its professional advisers.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.